Mineralys Therapeutics reports lorundrostat lowers systolic blood pressure in hypertension and sleep‑apnea trials
Mineralys Therapeutics presented new analyses from its Phase 3 Launch‑HTN trial showing that 46% of participants with difficult‑to‑treat hypertension achieved the AHA/ACC systolic target of <130 mmHg after 12 weeks of lorundrostat 50 mg. In the same session the company also reported final Phase 2 results of the Explore‑OSA trial, where lorundrostat 50 mg reduced morning systolic pressure by 11.1 mmHg at Week 4 in overweight adults with moderate‑to‑severe obstructive sleep apnea. Both studies reported favorable safety and tolerability.
Why it matters
The company says the data support its plan to seek FDA approval and label lorundrostat for blood‑pressure reduction in resistant hypertension, which could create a new therapeutic option for a large unmet patient population.
Key facts
- 146% of lorundrostat‑treated participants achieved an office systolic blood pressure below 130 mmHg at Week 12 in the Launch‑HTN trial. globenewswire.com
- 270% of lorundrostat‑treated participants achieved a systolic reduction of at least 10 mmHg in the Launch‑HTN trial. globenewswire.com
- 3In the Explore‑OSA trial, lorundrostat 50 mg reduced morning systolic blood pressure by 11.1 mmHg at Week 4. globenewswire.com
- 4The company aims to obtain FDA approval and clear labeling for lorundrostat in resistant hypertension. tradingview.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.